Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
From Reporter Signal to Delivery Insight
2026-09-15
A mechanistic framework for using capped firefly luciferase mRNA to distinguish delivery, intracellular release, translation, and biological response in translational research.
-
NF449 Selectively Targets Platelet P2X1 in Thrombosis
2026-09-15
The reference study established NF449 as a comparatively selective antagonist of the platelet P2X1 receptor and separated P2X1-dependent signaling from P2Y1 and P2Y12 activity. Its human platelet and mouse thrombosis experiments show that P2X1 blockade can reduce platelet activation and thrombus formation, while also demonstrating that higher exposure produces broader P2-receptor inhibition.
-
Caspase-4 Colorimetric Assay Kit Workflow
2026-09-14
Build a practical colorimetric caspase assay workflow for quantifying LEVD-dependent caspase-4 activity in inflammation, pyroptosis, and cell-fate studies. The guide also shows how to use the assay as a mechanistic bridge when evaluating ER-targeted peptide assemblies without mistaking caspase-4 activity for standalone proof of pyroptosis.
-
FCCP Workflows for Mitochondrial Biology
2026-09-14
FCCP converts mitochondrial membrane-potential biology into a controllable experimental perturbation for oxygen-consumption, ATP, HIF, and VEGF studies. This practical guide connects acute uncoupling with the 25-hydroxycholesterol–AMPK–STAT6 macrophage axis while separating established benchmarks from hypothesis-generating applications.
-
Recombinant Human Oncostatin M: Assay Workflows
2026-09-13
Use rh-Oncostatin M to build controlled proliferation, cytokine-release, and tumor–stroma experiments with a defined, tag-free reagent. This workflow also shows how to connect OSM perturbation to lipid-droplet and radioresistance readouts without overstating what current evidence proves.
-
Smoothened Signaling in Honeybee Olfaction
2026-09-12
Guo et al. characterize Apis mellifera Smoothened (Smo) and connect antenna-enriched Hedgehog signaling with olfactory receptor expression, electrophysiological responses, and odor-directed behavior. The study provides a useful insect-model framework for testing Smo function while showing why pharmacological dose, tissue context, and species differences must be considered before translation.
-
PRMT5, Splicing, and Glutamine Metabolism in Neuroblastoma
2026-09-11
The reference study identifies a linked vulnerability in MYCN-amplified neuroblastoma involving PRMT5-dependent splicing, epitranscriptomic control, and glutamine metabolism. Its combined use of pharmacologic perturbation, RNA sequencing, isotope tracing, m6A analysis, genetic knockdown, and mouse models provides a mechanistic framework for biomarker-led cancer metabolism research.
-
circStep Biosensor for Endogenous Protein Dynamics
2026-09-11
The reference study introduces circStep, an allosteric genetically encoded RNA biosensor that converts endogenous protein binding into a fluorogenic signal for live-cell localization and abundance tracking. By avoiding direct modification or overexpression of the protein of interest, the platform offers a complementary strategy for studying native protein relocalization and drug-induced transport dynamics.
-
3-hydroxybutyrate (BHBA) in Cell Assays
2026-09-10
A scenario-based guide to using 3-hydroxybutyrate (BHBA), SKU M1297, in viability, proliferation, cytotoxicity, and neuroprotection workflows. It addresses dose selection, solvent compatibility, assay interference, mechanistic controls, and evidence-based interpretation with links to product information and the relevant stroke study.
-
DiscoveryProbe Protease Inhibitor Library Workflow
2026-09-10
Build a defensible protease inhibition workflow around 825 pre-dissolved compounds, from biochemical profiling to cell-based mechanism testing. The approach connects broad protease activity modulation with the PSMD14–CARM1–FERMT1 axis reported in hepatocellular carcinoma research, while emphasizing orthogonal validation and assay troubleshooting.
-
Amitriptyline HCl in BBB Assay Design
2026-09-09
Amitriptyline HCl can serve as a mechanistically informative probe in blood-brain barrier research. This article translates a validated LLC-PK1-MDR1 permeability model into practical assay decisions that distinguish transport, efflux, and lysosomal trapping.
-
CH 223191: Decoding AhR Context in Cell Models
2026-09-09
CH 223191 is an aryl hydrocarbon receptor antagonist for separating AhR-dependent signaling from downstream correlation. This article connects dioxin toxicology with microbiota–tryptophan–AhR biology and develops a practical framework for interpreting receptor inhibition in epithelial and environmental models.
-
DAPI (hydrochloride) in Host–Pathogen Assays
2026-09-08
DAPI (hydrochloride) can serve as a nuclear and DNA-content readout within host–pathogen nanomedicine workflows. This article explains how to use its staining chemistry to separate host-cell injury, cell number, and cell-cycle effects from the antibacterial mechanisms reported for erythrocyte-mimicking nanovesicles.
-
Pexmetinib (ARRY-614) Assay Workflow Guide
2026-09-08
Build more informative cytokine assays with Pexmetinib (ARRY-614), a dual p38 MAPK and Tie2/Tek inhibitor suited to inflammatory signaling and hematologic research. This workflow connects concentration selection, phospho-signaling measurements, whole-blood testing, and reference-guided troubleshooting without treating pathway suppression as a single endpoint.
-
Imipenem Workflows for Antibacterial Research
2026-09-07
Imipenem supports controlled studies of bacterial killing, immune response modulation, and localized antimicrobial release. This workflow pairs free-compound assays with a titania nanotube interface inspired by a spatial proteomics study, helping researchers separate antibacterial activity from implant-driven inflammation.